scispace - formally typeset
K

Kai Rausalu

Researcher at University of Tartu

Publications -  22
Citations -  681

Kai Rausalu is an academic researcher from University of Tartu. The author has contributed to research in topics: Alphavirus & Virus. The author has an hindex of 11, co-authored 18 publications receiving 509 citations. Previous affiliations of Kai Rausalu include Estonian Biocentre.

Papers
More filters
Journal ArticleDOI

Antiviral activity of silymarin against chikungunya virus

TL;DR: Silymarin exhibited significant antiviral activity against chikungunya virus, reducing both CHIKV replication efficiency and down-regulating production of viral proteins involved in replication.
Journal ArticleDOI

The Antiviral Alkaloid Berberine Reduces Chikungunya Virus-Induced Mitogen-Activated Protein Kinase Signaling

TL;DR: Berberine is effective in multiple cell types against a variety of CHIKV strains, also at a high multiplicity of infection, consolidating the potential of berberine as an antiviral drug and highlighting the importance of the MAPK signaling pathways in the alphavirus infectious cycle.
Journal ArticleDOI

Reverse genetic system, genetically stable reporter viruses and packaged subgenomic replicon based on a Brazilian Zika virus isolate.

TL;DR: Efficient reverse genetic systems, genetically stable marker viruses and packaged replicons offer significant improvements for biological studies of ZIKV infection and disease, as well as for the development of antiviral approaches.
Journal ArticleDOI

Construction, properties, and potential application of infectious plasmids containing Semliki Forest virus full-length cDNA with an inserted intron.

TL;DR: An infectious plasmid of SFV, pCMV-SFV4, was constructed; its toxic effect was eliminated by intron insertion in the capsid protein encoding region and it produced virus with properties identical to those of wild-type SFV.
Journal ArticleDOI

Obatoclax Inhibits Alphavirus Membrane Fusion by Neutralizing the Acidic Environment of Endocytic Compartments

TL;DR: Obatoclax is a novel inhibitor of endosomal acidification that prevents viral fusion and that could be pursued as a potential broad-spectrum antiviral candidate.